Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...

Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.

US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...